After 2 weeks of treatment, there were no overlapping differential proteins between the first and second trials of samples, and after 12 weeks of treatment, there were two overlapping differential proteins: synaptic vesicle membrane protein vat-1 homolog (involved in the regulation of oxidoreductase activity) and amiloride-sensitive amine oxidase [copper-containing] (reported to be related to Alzheimer's disease and involved in the regulation of nitric oxide pathway). Here, AOC1 is linked to early-onset autosomal dominant Alzheimer disease.